Xiang Xiao-Juan, He You-Jian, Li Yu-Hong, Huang He, Xu Fei
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Ai Zheng. 2006 Jun;25(6):758-61.
BACKGROUND & OBJECTIVE: Peripheral T-cell lymphoma (PTCL) accounts for about 10%-15% of non-hodgkin's lymphomas (NHL), usually associated with short clinical course and poor prognosis. The over expression of survivin, a member of inhibitor of apoptotic protein (IAP), is regarded as a poor prognostic index in many malignant tumors. This study was to detect the expression of survivin in PTCL, and analyze its correlation to clinical features and prognosis of PTCL.
The expression of survivin in 51 specimens of naive PTCL was detected by immunohistochemistry. The correlations of survivin expression to clinical features and prognosis were analyzed by SPSS10.0 software.
The positive rate of survivin was 82.3%. Its expression had no significant correlations to sex, age, clinical stage, the number of extranodal lesions, performance status, serum level of lactate dehydrogenase, B symptoms, and international prognostic index (P>0.05). The 5-year overall survival rate of the 51 patients was 32.67%. The patients with positive survivin expression had poorer 5-year overall survival than negative patients (25.0% vs. 75.0%, P=0.03). Cox regression model showed that survivin was an independent poor prognostic index of PTCL.
Survivin is a useful prognostic index of PTCL. We can screen out the cases which may have poor prognosis early by combining survivin expression with IPI, and improve the treatment outcome of PTCL.
外周T细胞淋巴瘤(PTCL)约占非霍奇金淋巴瘤(NHL)的10% - 15%,通常临床病程短且预后差。凋亡抑制蛋白(IAP)家族成员survivin的过表达在许多恶性肿瘤中被视为不良预后指标。本研究旨在检测survivin在PTCL中的表达,并分析其与PTCL临床特征及预后的相关性。
采用免疫组织化学法检测51例初治PTCL标本中survivin的表达。应用SPSS10.0软件分析survivin表达与临床特征及预后的相关性。
survivin阳性率为82.3%。其表达与性别、年龄、临床分期、结外病变数量、体能状态、血清乳酸脱氢酶水平、B症状及国际预后指数均无显著相关性(P>0.05)。51例患者的5年总生存率为32.67%。survivin表达阳性患者的5年总生存率低于阴性患者(25.0%对75.0%,P = 0.03)。Cox回归模型显示survivin是PTCL独立的不良预后指标。
Survivin是PTCL有用的预后指标。将survivin表达与国际预后指数(IPI)相结合,可早期筛选出可能预后不良的病例,提高PTCL的治疗效果。